Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Pre-eclampsia poses no increased risk of neurocognitive impairment

28 Nov 2018

Women who have had pre-eclampsia do not exhibit clear neurocognitive impairment years after the index pregnancy, a study suggests.

Researchers used data from the Coronary Artery Risk Development in Young Adults cohort and looked at 568 parous women, of whom 193 had pre-eclampsia and 375 had normotensive pregnancy, without neurological disease or depression at baseline. Assessments included psychomotor speed (Digit Symbol Substitution Test), executive function (Stroop Test) and memory (Rey Auditory Verbal Learning Test).

Around 18 years after delivery, women in the pre-eclampsia group scored significantly lower on Digit Symbol Substitution Test (73.21 vs 75.87; p=0.047) and on the third trial of Stroop Test (correct answers: 38.85 vs 39.42; p=0.014; completion time: 44.02 vs 41.62 seconds; p=0.01) relative to those in the normotensive pregnancy group. Results for the Rey Auditory Verbal Learning Test did not significantly differ between the two groups.

However, the differences in psychomotor speed and executive function were attenuated after controlling for age, body mass index, hypertension, education and depression. Similar differences in neurocognitive scores were observed between women with other hypertensive disorders of pregnancy and normotensive pregnancy.

Evidence suggests that women with pre-eclampsia who indicate more anxiety and more depressive symptoms may be more vulnerable for cognitive failures in complex and perhaps more stressful daily life conditions. This is because executive functioning, or the control of complex, goal-directed behaviour is the cognitive ability most susceptible to stress. [Am J Obstet Gynecol 2014;211:37.e1-37.e9; Accid Anal Prev 2012;49:532-535]

Additional studies focusing on the relationship between subjective and objective neurocognitive functioning, symptoms of anxiety and depression, and brain white matter lesions are warranted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.